On Jan 08, major Wall Street analysts update their ratings for $Denali Therapeutics (DNLI.US)$, with price targets ranging from $24 to $87.
J.P. Morgan analyst Jessica Fye maintains with a buy rating, and adjusts the target price from $28 to $24.
BofA Securities analyst Tazeen Ahmad maintains with a buy rating, and adjusts the target price from $34 to $30.
Jefferies analyst Michael Yee maintains with a buy rating, and maintains the target price at $45.
Stifel analyst Paul Matteis maintains with a buy rating, and sets the target price at $37.
BTIG analyst Thomas Shrader maintains with a buy rating, and adjusts the target price from $35 to $32.
Furthermore, according to the comprehensive report, the opinions of $Denali Therapeutics (DNLI.US)$'s main analysts recently are as follows:
The recent disclosure regarding the Phase 2/3 HEALEY trial outcomes, which assessed an agonist of eIF2B in treating amyotrophic lateral sclerosis, led to some disappointment due to the DNL343's lack of success. This is particularly disheartening given the strong pre-clinical indications that suggested a reduction in the aggregation of significant ALS pathology drivers such as TDP-43. It has also been noted that this was among the final legacy projects for Denali, as the company's management is steering its development focus increasingly towards Television (TV) related projects.
Denali Therapeutics is anticipated to evolve into a commercial entity around late 2025 to early 2026, propelled by the potential accelerated FDA endorsement of tividenofusp alfa, an enzyme replacement treatment for Hunter syndrome. Thanks to its ability to penetrate the brain, DNL310 is expected to rapidly secure a substantial portion of the market share, currently held by Elaprase's $700M in annual sales. Additionally, Denali's preclinical 'Peak 2' initiatives aimed at Alzheimer's and Parkinson's diseases are considered promising prospects for the long term.
Here are the latest investment ratings and price targets for $Denali Therapeutics (DNLI.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間1月8日，多家華爾街大行更新了$Denali Therapeutics (DNLI.US)$的評級，目標價介於24美元至87美元。
摩根大通分析師Jessica Fye維持買入評級，並將目標價從28美元下調至24美元。
美銀證券分析師Tazeen Ahmad維持買入評級，並將目標價從34美元下調至30美元。
富瑞集團分析師Michael Yee維持買入評級，維持目標價45美元。
斯迪富分析師Paul Matteis維持買入評級，目標價37美元。
BTIG分析師Thomas Shrader維持買入評級，並將目標價從35美元下調至32美元。
此外，綜合報道，$Denali Therapeutics (DNLI.US)$近期主要分析師觀點如下：
關於評估eIF20億激動劑在治療肌萎縮側索硬化症方面的第二/第三階段 HEALEY 試驗結果的最新披露，引起了一些失望，因爲DNL343未能成功。這尤其令人沮喪，因爲強有力的臨牀前跡象表明減少了許多ALS病理驅動因數如TDP-43的聚集。此外，這被認爲是Denali的最後幾個遺留項目之一，因爲公司的管理層越來越多地將其開發重點轉向與電視相關的項目。
Denali Therapeutics預計將在2025年底至2026年初轉變爲一家商業實體，這主要得益於FDA對tividenofusp ALFA的潛在加速批准，該藥物是用於亨特綜合徵的酶替代治療。由於其能夠穿透大腦，DNL310預期將迅速佔據市場份額，目前該市場由Elaprase的70000萬美元年銷量所佔。此外，Denali針對阿爾茨海默病和帕金森病的臨牀前「Peak 2」計劃被認爲是長期內的有希望前景。
以下爲今日7位分析師對$Denali Therapeutics (DNLI.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
